The drug directly targets the insulin like-growth factor (IGF) and insulin pathway, both of which are known to have tumor promoting effects, while indirectly, metformin has been reported to be an inhibitor of the mitochondrial complex I respiratory chain, inhibiting the tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS), increasing lactate production, and rendering the tumor cells energetically inefficient [45, 46]. The gene discussed is IGF1; the disease is neoplasm.